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Abstract
Background: Creutzfeldt-Jakob disease (CJD) is a rare, rapidly progressive fatal central nervous system disorder, which
consists of three main catalogues: sporadic, familial, and iatrogenic CJD.
Methodology/Principal Findings: In China, the surveillance for CJDstartedin2006, covering 12 provincialCentersfor Disease
Control and Prevention (CDCs) and 15 hospitals. From 2006 to 2010, 624 suspected patients were referred to China CJD
surveillance. The epidemiological, clinical and laboratory features of sporadic CJD (sCJD) were analysed. Both groups of
probable and possible sCJD showed highest incidences in the population of 60 to 69 year-olds. The most common presenting
symptoms were progressive dementia and mental-related symptoms (neurological symptoms including sleeping turbulence,
depression, anxiety and stress). Among the four main clinical manifestations, myoclonus was more frequently observed in the
probable sCJD patients. About 2/3 of probable sCJD cases showed positive 14-3-3 in CSF and/or periodic sharp wave
complexes (PSWC) in electroencephalography (EEG). The presence of myoclonus was significantly closely related with the
appearanceof PSWC in EEG. Polymorphisms of codon 129 in PRNP of the notified cases revealed a highlypredominant M129M
genotype in Han Chinese. Among 23 genetic human prion diseases, ten were D178N/M129M Fatal familial insomnia (FFI) and
five were T188K genetic CJD (gCJD), possibly indicating a special distribution of gCJD-related mutations in Han Chinese.
Conclusion: From the period of 2006 to 2010, 261 patients were diagnosed as sCJD and 23 patients were diagnosed as
genetic human prion diseases in China. The epidemiological, clinical and laboratory analysis data were consistent with the
characteristics of sporadic CJD, which provide insight into the features of CJD in China.
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Introduction
Creutzfeldt-Jakob disease (CJD) is a rare, rapidly progressive
fatal central nervous system (CNS) disorder. It consists of three
main catalogues: sporadic, familial and iatrogenic CJD. The
reasons of sporadic CJD are still unclear. Genetic human prion
disease is associated with a range of mutations in the prion protein
gene (PRNP) on Chromosome 20 [1], which include genetic or
familial CJD, as well as other genetic human transmissible
spongiform encephalopathies (TSE), such as Gerstmann-Stra ¨uss-
ler-Scheinker disease (GSS) and fatal familial insomnia (FFI).
Iatrogenic CJD is acquired by various iatrogenic procedures, such
as treatment with human pituitary growth hormones, dura mater
and cornea grafts, deep brain electrodes and neurosurgery [2].
Since 1996, a new acquired human CJD, variant CJD (vCJD), has
been recognized worldwide, which is confirmed to link to bovine
spongiform encephalopathy (BSE) [3]. Up to now, 221 vCJD cases
have been described, including one Japanese case.
Based on the current diagnostic criteria for sporadic CJD (sCJD)
issued by WHO, the possible diagnosis of sCJD is based on the
clinical manifestations, that is progressive dementia plus at least
two out of four following signs: myoclonus, visual or cerebellar
disturbance, pyramidal or extrapyramidal dysfunction and akinet-
ic mutism. The probable diagnosis of sCJD needs further clinical
data, such as typical changes in EEG and MRI, or laboratory data,
such as a positive 14-3-3 protein test in cerebrospinal fluid (CSF).
An absolutely definite diagnosis of any form of CJD usually
requires either pathological or pathogenic examination of brain
tissues.
As the great impact of the outbreak of BSE and the emerging
cases of vCJD on public health, many countries or regions,
particularly European countries, have started or restarted the
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for CJD was conducted in China, which was supported by Chinese
Center for Disease Control and Prevention (CCDC). Up to the
end of 2010, 284 various CJD and human TSE cases were
identified and diagnosed. In this paper, we comparably describe
the epidemical, clinical and laboratory features of Chinese CJD
patients based on this surveillance.
Materials and Methods
Ethics statement
Usage of the human clinical samples in this study, which was
one of the important clinical materials in China CJD Surveillance
System, has been approved by the Ethical Committee of National
Institute for Viral Disease Prevention and Control, China CDC.
Figure 1. The age distribution of probable and possible sCJD cases. The black column indicates probable sCJD, the grey column indicates
possible sCJD and the curve represents the total numbers.
doi:10.1371/journal.pone.0024231.g001
Figure 2. The geographic distribution of probable and possible sCJD cases based on the permanent residences. The numbers of
probable and possible sCJD cases in each province were showed as X (X), respectively.
doi:10.1371/journal.pone.0024231.g002
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China CJD Surveillance Center.
Constitution of China CJD surveillance
China CJD surveillance started formally in 2006, under the
framework of the national communicable surveillance network of
the CCDC. It consisted of 10 provincial CDCs and 11 hospitals,
distributing in Beijing, Shanghai, Tianjin, Chongqing, Jilin,
Shaanxi, Hubei, Guangdong, Guizhou and Anhui. In 2008, two
provincial CDCs and three hospitals in Henan and Xinjiang
joined in the network. The surveillance program was approved by
the Ethical Review Committee of CCDC. Based the surveillance
documents, the patients who have symptoms in accordance with
the diagnosis criteria for at least possible sCJD or other subtypes of
human prion diseases, or any case that is believed by the
physicians to be necessary to exclude the possibility of CJD can be
referred as a ‘‘suspected CJD case’’ to the surveillance system. The
clinical data and specimens of the suspected patients were
collected by the clinicians from hospitals, while the epidemiolog-
ical data were collected by the staff of provincial CDCs. The
collected data and samples were referred to the national reference
laboratory for human prion disease, CCDC, for laboratory tests
and final diagnosis.
Collections of clinical and epidemiological data
The clinical and epidemiological data of suspected CJD patient
were collected with the designed questionnaires. The clinical data
included the general information, main clinical manifestations, the
presenting symptoms and clinical examinations (for example, CT,
MRI, EEG and routine CSF biochemistry). The epidemiological
data included inhabitancy, family history, anamnesis (surgical or
neurosurgical history, organ transplantation, blood donation and
transfusion, use of extracts of pituitary or other blood products),
and profession (especially medical staff, veterinarians and
butchers).
Laboratory tests
The specimens of blood, CSF and brain tissues of the suspected
patient were collected by the sentinel hospital. All samples were
transported to the national reference laboratory for human prion
disease in CCDC. The peripheral blood leukocytes were used for
sequencing analysis of PRNP and polymorphism of codon 129,
with an automatic genetic analyzer (ABI3130XL). CSF samples
were obtained by routine lumbar puncture and analysed by
Western immunoblot to detect the 14-3-3 protein. Brain tissues
obtained from autopsy or biopsy were applied into neuropatho-
logic assays and/or PrP
Sc detections with immunohistochemistry
and/or Western blot. The standard operation procedure (SOP) of
each test was well documented in the CJD surveillance program,
which was described previously [4].
Case definition
The suspected CJD cases reported from CJD surveillance were
diagnosed and subtyped based on the diagnostic criteria issued by
CCDC, which was constituted based on the diagnostic criteria for
CJD issued by WHO. Since 2010, high signal in caudate/putamen
on MRI brain scan has been added into the criteria according to
the renewed version issued by WHO [5]. The final diagnosis was
made by an expert board including neurologists, neuropatholo-
gists, epidemiologists and laboratory staff.
Statistical analysis
All statistical analysis were performed with the Chi-square test
using the SPSS 11.5 statistical software programme and statistical
significance corresponds to a p value,0.05.
Results
Between 2006 and 2010, 624 suspected CJD cases were referred
to the China CJD surveillance program. The notified numbers of
suspected CJD patients increased year by year, but without
seasonal relativity. The resident sites of reported cases distributed
widely in mainland of China, but most cases were reported from
the hospitals in larger cities. Based on the diagnostic criteria for
Table 1. The presenting symptoms of the probable and
possible sCJD patients.
clinical manifestation case number
probable possible P
progressive dementia 79 (48.5%) 39 (40.6%) 0.2219
mental syndrome
1 40 (24.5%) 21 (21.9%) 0.6261
cerebellum syndrome 27 (16.6%) 16 (16.7%) 0.9830
pyramidal or extrapyramidal dysfunction 27 (16.6%) 17 (17.7%) 0.8132
visual disturbance 16 (9.8%) 10 (10.4%) 0.8768
slow progressive dementia
2 17 (10.4%) 16 (16.7%) 0.1467
cerebral stroke 3 (1.8%) 1 (1.0%) 0.6152
dizziness 4 (2.5%) 1 (1.0%) 0.4259
sleeping disturbance 1 (0.8%) 1 (1.0%) 0.7043
lower limbs inability 2 (1.3%) \ 0.2768
speech disability \ 1 (1.0%) 0.1926
headache 2 (1.3%) \ 0.2768
1including sleeping turbulence, depression, anxiety and stress etc.
2when the dementia persists longer than one year progressively without other
manifestations.
doi:10.1371/journal.pone.0024231.t001
Table 2. The appearances of main clinical manifestations except progressive dementia in probable and possible sCJD patients.
case number myoclonus
visual or cerebellar
disturbance
pyramidal or
extrapyramidal
dysfunction akinetic mutism
Probable sCJD 163 121 (74.2%) 93 (57.1%) 127 (77.9%) 62 (38.0%)
Possible sCJD 96 54 (56.3%) 56 (58.3%) 76 (79.2%) 29 (30.2%)
P 0.0028 0.841 0.8134 0.2469
doi:10.1371/journal.pone.0024231.t002
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patients were diagnosed as possible sCJD. Only a few cases had
brain biopsies, among them two cases were diagnosed as definite
sCJD in term of positive presences of PrP
Sc in brain tissues with
Western blots or immunohistochemistry. In addition, 23 genetic
human prion diseases were diagnosed based on the genetic assays
of PRNP, including ten FFI (D178N/M129M) cases, two GSS
(P102L) cases, five T188K gCJD cases, two G114V gCJD cases,
one E196K gCJD case, one E200K gCJD case, one R208H gCJD
case and one gCJD cases with one extra-octarepeat insertion.
Some of the genetic prion diseases have been already described as
case report [6,7,8,9].
General sociodemographic features
Out of 261 sCJD patients, 146 were males and 115 were
females, with the gender ratio of 1.27:1. The onset age of
probable sCJD ranged from 21 to 82 y, with the median age of
61 y, while that of possible sCJD ranged from 18 to 80 y, with the
median age of 60 y. Both groups of sCJD showed highest
incidences in the population of 60 to 69 year-olds (Fig. 1). The
patients distributed widely in term of their permanent resident
sites (Fig. 2), 78.4% lived in the city and 21.6% in the
countryside. The occupations and educational levels of sCJD
patients varied considerably. Five cases were retired medical staff,
but after careful investigation, we excluded the possibility of
iatrogenic infection. All cases showed no linkage with their
anamnesis. The onsets occurred all year round, without seasonal
specificity.
Clinical features
The presenting symptoms of the reported sCJD cases were
multifarious. Progressive dementia was the most common
presenting symptoms that were noted by 118 out of 259 probable
and possible sCJD (45.6%) patients. Mental syndrome (including
sleeping turbulence, depression, anxiety and stress) appeared in 61
patients (23.6%), followed by pyramidal or extrapyramidal
dysfunction (17.0%), cerebellum syndrome (16.6%), slow progres-
sive dementia (12.7%) and visual disturbance (10.0%). Analysis of
the appearance percentages of the presenting clinical manifesta-
tions in probable and possible sCJD patients revealed similar
patterns (Table 1). Only the percentages of slow progressive
dementia that was persistent longer than one year in the group of
possible sCJD were slightly higher than that in probable sCJD, but
without statistical significance.
Almost all probable and possible sCJD patients displayed
obviously progressive dementia in their clinical courses. Except for
progressive dementia, the presence of four other clinical
manifestations included in the diagnostic criteria for sCJD,
myoclonus, visual or cerebella disturbance, pyramidal or extrapy-
ramidal dysfunction and akinetic mutism, were compared between
two groups. Pyramidal or extrapyramidal dysfunction was the
most commonly observed sign in both probable and possible
patients, which accounted 77.9% and 79.2%, respectively. Visual
or cerebellar disturbances are noted comparably in probable
(57.1%) and possible (58.3%) sCJD patients. Akinetic mutism
appeared in 38.0% improbable and 30.2% possible patients.
Myoclonus was more frequently observed in the group of probable
sCJD, showing statistical differences (Table 2).
As sCJD has no special clinical manifestation, the appearances
of symptoms and signs may vary considerably. Analysis of the
frequencies of those four main manifestations in the groups of
probable and possible sCJD showed the similar tendencies, that
small portions of the patients had all four neurological manifes-
tations. However, the number of patients who had three signs in
the group of probable sCJD were markedly larger than that of
possible sCJD (P=0.0055). In contrast, a remarkably larger
number of possible sCJD patients (68.8%) showed only two
symptoms than that of probable sCJD ones (47.9%) (P=0.0011,
Table 3).
Laboratory features
Appearances of 14-3-3 protein in CSF and typical PSWC on
EEG were important indicators for probable sCJD. Most of the
reported cases had only one examination of CSF 14-3-3 and/or
EEG during their clinical course. Among 163 probable sCJD
patients, 153 patients had CSF 14-3-3 tests and 69.3% (106) were
positive, while 148 patients had EEG examinations and 63.5% (94)
showed PSWC. Both 14-3-3 in CSF and PSWC on EEG could be
detected in an extended span of time after onset of symptoms
(Fig. 3), among them the earliest and latest data of CSF 14-3-3
were 10 and 680 (median: 95) days after onset, while those of
PSWC in EEG were 20 and 340 (median: 78.5) days after onset.
Table 3. The frequencies of other four clinical manifestations except progressive dementia in probable and possible sCJD patients.
case number having four clinical features having three clinical features having two clinical features
Probable sCJD 163 24 (14.7%) 61 (37.4%) 78 (47.9%)
Possible sCJD 96 10 (10.4%) 20 (20.8%) 66 (68.8%)
P 0.3224 0.0055 0.0011
doi:10.1371/journal.pone.0024231.t003
Figure 3. The distribution of the times positively detecting 14-
3-3 in CSF (blue dot) and/or PSWC on EEG (green dot) after the
onset in the probable sCJD patients. The black lines indicate the
median data.
doi:10.1371/journal.pone.0024231.g003
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was found between the groups of CSF 14-3-3 positive and EEG
abnormality. In terms of the presence of four main clinical
manifestations, more percentage of the patients with EEG
abnormality showed myoclonus during their clinical courses than
those with 14-3-3 positive (P=0.0421), whereas other three
manifestations distributed comparably in these two groups.
In all probable sCJD cases, 138 patients had both examinations
of EEG and CSF 14-3-3 during their clinical course. 62 cases
showed 14-3-3 positive in CSF and PSWC on EEG, 44 were only
CSF 14-3-3 positive, 32 were only PSWC in EEG. The
appearances of the four main clinical features were comparably
analyzed among various groups. Table 4 showed that roughly 3/4
and 2/3 patients in each group had pyramidal or extrapyramidal
dysfunction and visual or cerebellar disturbance, respectively.
Myoclonus was apparently frequently observed in the patients with
PSWC in EEG (P=0.008) and in those with both CSF 14-3-3 and
PSWC in EEG (P=0.0076) (Table 4), showing an obviously EEG
abnormality-related manner. Akinetic mutism seemed to be more
frequent in the group of CSF 14-3-3 positive and PSWC in EEG,
but without statistic difference.
Analysis of the frequencies of four main neurologic features
among above three groups revealed that more percentages of the
patients with both abnormalities in CSF 14-3-3 and PSWC on
EEG had four and three symptoms during clinical courses, but
without statistic difference compared with the patients with only
one abnormality either in CSF 14-3-3 or on EEG (Table 5).
However, significantly fewer patients with both abnormalities in
CSF 14-3-3 and EGG had only two symptoms than those that
were only CSF 14-3-3 positive (P=0.006). No statistic difference in
the frequencies of four main neurologic features was observed
between the groups of only CSF 14-3-3 positive and only PSWC
on EEG.
PRNP sequences of 560 notified suspected CJD patients were
analyzed. 548 patients showed a methionine homozygous genotype
at codon 129 (97.9%), whereas 12 were methionin/valine
heterozygote (2.1%) and none was valine/valine homozygote,
revealing a typical Han Chinese frequency [10]. Only one person
showed the E219K polymorphism. Analysis of the codon 129
polymorphism in probable and possible sCJD identified similar
features, showing a highly predominant M129M genotype (96.9%
inprobableand99.0%inpossible).22 genetichumanprion diseases
were diagnosed during 2006 to 2010 based on PRNP sequencings,
all of them being M129M homozygote. Interestingly, ten D178N/
M129M FFI and five T188K gCJD cases were identified, which
accounted for 43.5% and 21.7% of diagnosed genetic human prion
diseases. It may indicate that the genotypes of D178N/M129M and
T188K distribute relatively widely among Han Chinese.
Discussion
In this report, we describe the clinical, epidemiological and
laboratory features of 261 sCJD cases who are diagnosed under
the framework of surveillance network in mainland of China from
2006 to 2010. These included 2 definite, 163 probable and 96
possible cases of sCJD. The general sociodemographic character-
istics of Chinese sCJD cases are coincident well with those
described elsewhere [4], without detectable linkage among the
cases. A large number of sCJD patients display their clinical
manifestations at the ages of 60 to 69 year-old. The patients
distribute widely in whole country according to their permanent
residence. Some regions have more cases, e.g. Beijing, Shanghai
and a couple of eastern provinces, but this may reflect merely a
good knowledge of CJD among the local clinician and relatively
developed medical service, instead of the actual morbidity. More
male Chinese sCJD cases have been detected with a gender ratio
of 126.9:100, which is higher than the average gender ratio
(106.3:100) in mainland of China. The sCJD patients have a wide
range of professions.
Regardless of probable or possible sCJD, progressive dementia is
inevitably notified during the progression of disease [11]. The
presentingsymptomsof the probable and possible sCJD patients are
quite similar, in which progressive dementia is most detectable,
followed by mental syndrome, cerebellum syndrome and pyramidal
Table 4. Comparison of the results of 14-3-3 and EEG with the appearances of clinical manifestations in 138 probable sCJD
patients with two examinations.
case number myoclonus
visual or cerebellar
disturbance
pyramidal or extrapyramidal
dysfunction akinetic mutism
14-3-3 44 24 (54.5%) 27 (61.4%) 35 (79.5%) 15 (34.1%)
EEG 32 29 (90.6%)* 18 (56.3%) 27 (84.4%) 11 (34.4%)
14-3-3+EEG 62 49 (79.0%)** 36 (58.1%) 46 (74.2%) 28 (45.2%)
*compared with the data of 14-3-3 positive, P=0.0008.
**compared with the data of 14-3-3 positive, P=0.0076.
doi:10.1371/journal.pone.0024231.t004
Table 5. The frequencies of other four clinical manifestations except progressive dementia in 138 probable sCJD patients with two
examinations.
case number having four clinical features having three clinical features having two clinical features
14-3-3 44 5 (11.4%) 10 (22.7%) 29 (65.9%)
EEG 32 4 (12.5%) 12 (37.5%) 16 (50.0%)
14-3-3+EEG 62 13 (21.0%) 25 (40.3%) 24 (38.7%)*
*compared with the data of 14-3-3 positive, P=0.006.
doi:10.1371/journal.pone.0024231.t005
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disease, other neurologic symptoms have been gradually observed.
Although there is no special difference in term of the presence of
neurologic symptoms between probable and possible sCJD,
remarkably more percentages of probable sCJD patients have three
main clinical features than that of possible sCJD. Moreover, among
the four main clinical manifestations, myoclonus is more frequently
released in the probable sCJD patients. It may highlight a more
severe and extended neuropathologic damage in probable sCJD
patients.
As the important diagnostic markers for sCJD, the data of CSF
14-3-3 Western blot and EEG in notified cases have been collected
through CJD surveillance network. Both 14-3-3 in CSF and
PSWC on EEG can be detected in an extended range during
clinical courses of the probable sCJD patients, among them CSF
14-3-3 seems to be detectable in a more extended range. Two
patients with relatively long clinical courses more than 500 days
are CSF 14-3-3 positive, but negative in EEG. Although probable
sCJD patients show high ratios of both CSF 14-3-3 positive and
PSWC in EEG, only roughly approximately 45% of patients who
have undergone those two examinations are positive for both. It
emphasizes again the irreplaceable roles of CSF 14-3-3 and PSWC
on EEG in diagnosis of sCJD. From our data, it seems that the
presence of myoclonus is more closely related with the appearance
of PSWC on EEG.
All 560 notified cases that have performed PRNP analysis are
Han Chinese. Similar to that previously reported [4], M129M are
highly predominant either in notified patients or sCJD patients.
The percentage of M129M in sCJD patients is slightly higher than
that in normal Han Chinese [10], possibly indicating a CJD-
related sensitivity. 23 genetic human prion diseases have been
identified, which occupies 7.8% of all diagnosed human prion
diseases in the past five years. Surprisingly, ten are D178N/
M129M FFI and five are T188K gCJD, which accounting for the
majority of the reported genetic human prion diseases. This differs
from the distribution of genetic human TSE in Caucasian
populations [12,13], possibly suggesting a special PRNP patterns
in Han Chinese. Besides FFI cases, almost all other human TSE
are misdiagnosed as sCJD until PRNP gene sequencing. It implies
again that sequence analysis of PRNP is an indispensable
methodology for detection of gCJD, especially for the patients
without detectable family histories.
The China CJD surveillance network is a hospital-based
surveillance that contains 15 large hospitals in 12 cities. Most
notified cases drive from the sentinel hospitals, except Beijing and
Shanghai where the cases are reported from many different
hospitals. It possibly reflects merely the good knowledge of CJD
and high level of medical service in Beijing and Shanghai. CJD is
not a notifiable disease in China. Even in the CJD surveillance
covered cities, only 1 to 2 hospitals are involved in the surveillance
activities. Hence, it is still too early to define the CJD morbidity
and mortality based on population-size in China. An extremely
low percentage of postmortems performed in the Chinese
population makes it difficult to definitely diagnose CJD. Compre-
hensive understanding of the other features of CJD, besides its
neuropathology, shows special benefits for Chinese neurologists
and public health staff. Nevertheless, our five-year CJD surveil-
lance mission not only provides the meaningful CJD data in
China, but also makes it possible to perform the population-size
based CJD surveillance in some special regions in the near future,
such as Beijing and Shanghai.
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